Paragon 28 Acquisition Contributes to Growth
The Paragon 28 acquisition added 0.7% to consolidated net sales growth in Q2, with a larger impact in the S.E.T. category (2.8%).
ZIMMER BIOMET HOLDINGS, INC. is expected to release its Q3 2026 10-Q filing on November 3, 2026, before market open. Last quarter: Zimmer Biomet’s Q2 FY2026 earnings surged 29.8% as the Paragon 28 acquisition and strong robotic and bone cement sales drove revenue growth of 4.8%.
EPS Estimate
$1.89
Revenue Estimate
$2.06B
Analyst consensus from Finnhub and Financial Modeling Prep. Actual results posted within minutes of the SEC filing on the ZBH page.
Drawn from management commentary in the Q2 2026 10-Q:
The Paragon 28 acquisition added 0.7% to consolidated net sales growth in Q2, with a larger impact in the S.E.T. category (2.8%).
Sales in this category grew 21.1% year-over-year, driven by heightened demand for ROSA Robots and bone cement products.
A favorable adjustment of approximately $30 million related to probable U.S. tariff refunds was recognized in the six‑month period, lowering cost of products sold as a percentage of revenue.
Revenue
$2.18B
+4.80% YoY
EPS (Diluted)
$1.03
+33.77% YoY
Operating Income
$326.1M
+8.70% YoY
Add ZBH to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.